NCT00558545 - A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Human Mammary Carcinoma

Interventions

DRUG

AEG35156

AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.

Trial Locations (10)

12206

New York Oncology & Hematology P. C., Albany Cancer Center, Albany

23502

Virginia Oncology Associates, Norfolk

29605

Cancer Centers of the Carolinas, Greenville

34761

Cancer Centers of Florida, P.A., Ocoee

45409

Dayton Oncology & Hematology, P.A., Dayton

46219

Central Indiana Cancer Center, Indianapolis

75246

Sammons Cancer Center, Dallas

75702

Tyler Cancer Center, Tyler

80218

Rocky Mountain Cancer Center, Denver

98684

Northwest Cancer Specialists, P. C., Vancouver